by Alex Bajjon | Feb 1, 2019 | Briefings, UK
Introduction This case relates to a European patent (EP2269603) in the name of Novartis relating to derivatives of rapamycin. Claim 1 of the patent covers: “40-O-(2-hydroxyethyl)-rapamycin in combination with exemestane for use in the treatment of hormone...
by David Eyre | Feb 1, 2019 | Briefings, EPO
Can you patent a genetically modified organism? While Article 53(b) EPC is clear that essentially biological methods of producing an organism, i.e. crossing and selection, are not patentable there has been ongoing debate as to whether the organisms resulting from...
by Sean Hughes | Jan 1, 2019 | Briefings, US & International
The time-consuming and costly regulatory review of new pharmaceuticals led to the Supplementary Protection Certificate (SPC) system being introduced in 1992. The SPC system is designed to compensate for the shortening in effective patent term that arises from the...
by Juliette Boynton | Nov 1, 2018 | Briefings, UK
Background Ice-World, who is the proprietor of European patent No. 1462755, makes mobile ice rinks and leases them to third parties. Icescape also design and make mobile ice rinks, although in the past have operated a mobile ice rink leased to them from Ice-World....
by Juliette Boynton | Nov 1, 2018 | Briefings, UK
Warner-Lambert originally developed its compound pregabalin, which it sold under the mark Lyrica, as an anti-convulsant, anti-anxiety, anti-psychotic medication, in particular for the treatment of epilepsy and generalised anxiety disorder. It obtained patent...
Recent Comments